Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)
Close on Nov 18, 2026Market cap $99.30MP/E –Yield –
Outlook Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Outlook Therapeutics's price to book ratio was 42.3× on Jul 31, 2023, against 5.2× a year earlier. Over the last 3 years it ranged from 4.7× to 58.5×, with a median of 27.1×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Jul 31, 2023 | 42.3× | +14.2 |
| 2022 | Dec 30, 2022 | 28.1× | −24.0 |
| 2021 | Dec 31, 2021 | 52.1× | −6.4 |
| 2020 | Dec 31, 2020 | 58.5× | – |
See a number that looks wrong?